[시장보고서]미국의 뇌종양 시장 규모, 점유율, 동향 분석 보고서 : 종양 유형별, 치료 유형별, 부문 예측(2025-2034년)

미국의 뇌종양 시장 규모, 점유율, 동향 분석 보고서 : 종양 유형별, 치료 유형별, 부문 예측(2025-2034년)

U.S. Brain Tumor Market Size, Share & Trends Analysis Report By Tumor Type (Malignant, Non-malignant), By Treatment Type (Surgery, Radiation Therapy, Interventional Device-Based Procedures, Chemotherapy), And Segment Forecasts, 2025 - 2034

상품코드 : 1701276

리서치사 : Grand View Research

발행일 : 2025년 03월

페이지 정보 : 영문 110 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,000

￦ 7,224,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,000

￦ 8,668,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,000

￦ 11,558,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

미국의 뇌종양 시장의 성장과 동향 :

Grand View Research의 최신 보고서에 따르면 미국의 뇌종양 시장은 2034년까지 43억 5,000만 달러에 달하고, 2025년부터 2034년까지 연평균 9.87%의 성장률을 보일 것으로 예측됩니다.

예를 들어, National Brain Tumor Society의 보고서에 따르면, 현재 약 100만 명의 미국인이 원발성 뇌종양을 앓고 있으며, 효과적인 치료법을 필요로 하는 환자층이 상당수 존재한다고 합니다. 이 중 2023년에는 약 72%가 양성, 28%가 악성으로 분류되어 다양한 치료 니즈와 접근법이 필요하다는 것을 보여줍니다. 또한 같은 자료에 따르면 비악성 수막종은 원발성 비악성 뇌종양 중 가장 많은 유형으로 전체 뇌종양의 약 39.7%, 전체 비악성 뇌종양의 55.4%를 차지합니다.

공공 및 민간 부문의 자금 지원과 투자 증가도 시장 확대의 원동력이 되고 있으며, 시장 성장을 더욱 촉진하고 있습니다. 또한 표적치료, 면역치료, 수술적 치료의 발전을 포함한 치료 옵션의 지속적인 혁신이 시장 확대에 중요한 역할을 하고 있습니다. 정밀의료의 혁신은 보다 개인화된 치료 계획을 가능하게 하고, 환자 치료 결과를 개선하며, 투자를 유치하고 있습니다.

시장의 성장 단계는 높고, 그 속도는 가속화되고 있습니다. 미국의 뇌종양 시장은 뇌종양 유병률 증가, 더 나은 진단 도구, 표적 치료와 같은 치료법 혁신, 정부, 비영리 단체 및 민간 부문의 뇌종양 연구에 대한 막대한 자금 지원, 수술, 방사선 치료, 화학 요법과 같은 다양한 치료 옵션의 가용성 등으로 인해 성장세를 보이고 있습니다.

미국의 뇌종양 시장 보고서 하이라이트

종양 유형별로는 뇌종양 유병률 증가, 교모세포종 및 고악성 악성 뇌종양 발생률 증가로 인해 2024년 악성 부문이 가장 큰 매출 점유율을 차지했습니다.
교모세포종을 포함한 악성 뇌종양은 보통 수술, 항암화학요법, 방사선 치료를 병행하는 적극적인 치료법이 필요한 경우가 많습니다.
치료 유형에 따라 몇 가지 설득력 있는 요인으로 인해 2024년에는 수술 부문이 가장 큰 시장 점유율을 차지했습니다. 첫째, 외과적 개입은 많은 유형의 뇌종양, 특히 교모세포종과 같은 악성 종양을 관리하기 위한 주요 접근 방식입니다. 개두술 및 종양 절제술을 포함한 수술적 치료는 종양을 가능한 한 많이 제거하여 뇌에 가해지는 압력을 완화하고 증상을 완화하며 전반적인 환자 예후를 개선하는 것을 목표로 합니다.

시장 계통 전망
- 상위 시장 전망
- 관련/부수 시장 전망
시장 역학
- 시장 성장 촉진요인 분석
- 시장 성장 억제요인 분석
- 시장 기회 분석
- 시장이 해결해야 할 과제 분석
미국의 뇌종양 시장 분석 툴
- 업계 분석 - Porter의 Five Forces 분석
- PESTEL 분석

제4장 미국의 뇌종양 시장 : 종양 유형 추정·동향 분석

정의와 범위
종양 유형 시장 점유율, 2024년과 2034년
부문 대시보드
미국의 뇌종양 시장 : 종양 유형별 전망
시장 규모와 예측 및 동향 분석, 2024년-2034년(종양 유형별 치료를 받는 환자수)
- 악성
- 비악성

제5장 미국의 뇌종양 시장 : 치료 유형 추정·동향 분석

정의와 범위
치료 유형 시장 점유율, 2024년과 2030년
부문 대시보드
미국의 뇌종양 시장 : 치료 유형별 전망
악성 종양 치료 유형 시장 규모와 예측 및 동향 분석, 2024년-2034년
- 수술
- 방사선 치료
- 중재적 장치 기반 절차
- 화학요법
- 표적치료
- Tumor Treating Fields (TTF)
- 레이저 조직내 온열 요법(LITT)
- 외과적 표적 방사선 요법
- 카테터를 이용한 초음파 열응고술
- 집속 초음파(FUS)
- 저강도 초점식 초음파(LIFU)
비악성 종양 치료 유형 시장 규모와 예측 및 동향 분석, 2024년-2034년
- 수술
- 방사선 치료
- 기타 모니터링 기기

제6장 경쟁 구도

주요 시장 진출기업의 최근 동향과 영향 분석
기업/경쟁 분류
- 혁신기업
벤더 구도
- 주요 유통업체 및 채널 파트너 리스트
- 주요 고객
- 주요 기업의 시장 점유율 분석(2024년)
- GT Medical Technologies, Inc.
- Novocure
- ZAP Surgical Systems, Inc.
- Aesculap, Inc.-a B. Braun company
- Accuray Incorporated
- Carthera
- Alpheus Medical Inc.
- Alpha Tau Medical Ltd
- Elekta
- IMRIS Inc.
- Medtronic
- Monteris
- Openwater
- Acoustic MedSystems, Inc.
- NaviFUS Corp
- Insightec
- Varian Medical Systems, Inc.(Siemens Healthineers)
- RefleXion
- MagnetTx Oncology Solutions Ltd.
- NICO Corporation(Stryker)
- Terumo Interventional Systems
- Boston Scientific Corporation
- Koninklijke Philips NV
- IBA Worldwide

LSH

영문 목차

영문목차

U.S. Brain Tumor Market Growth & Trends:

The U.S. brain tumor market is anticipated to reach USD 4.35 billion by 2034, growing at a CAGR of 9.87% from 2025 to 2034, according to a new report by Grand View Research, Inc. The market growth is primarily driven by the increasing prevalence of brain cancer and rising number of brain tumor diagnoses in the U.S. For instance, according to the National Brain Tumor Society report, an estimated one million Americans are currently living with a primary brain tumor, highlighting a substantial patient population in need of effective treatment options. Among these tumors, approximately 72% were classified as benign, while 28% were malignant in 2023, indicating a diverse range of treatment needs and approaches. Furthermore, according to the same source, non-malignant meningiomas represent the most prevalent type of primary non-malignant brain tumors, comprising approximately 39.7% of all brain tumors and 55.4% of all non-malignant tumors.

Increasing funding and investments from both public and private sectors are also driving market expansion and further fueling market growth. Furthermore, continued innovation in treatment options, including targeted therapies, immunotherapies, and advancements in surgical techniques is playing a crucial role in market expansion. Breakthroughs in precision medicine allow for more personalized treatment plans, which enhance patient outcomes and attract investment.

The market growth stage is high, and the pace of the market growth is accelerating. The U.S. brain tumor market is characterized by growth owing to the rising prevalence of brain tumors, along with better diagnostic tools, innovations in treatment modalities, such as targeted therapies, substantial funding for brain tumor research from government, non-profits, and private sectors, and availability of a wide range of treatment options, including surgery, radiation therapy, and chemotherapy, among others.

U.S. Brain Tumor Market Report Highlights:

Based on tumor type, the malignant segment accounted for the largest revenue share in 2024 driven by the rising prevalence of brain cancer and increasing incidence of glioblastoma and high-grade malignant brain tumors
Malignant brain tumors, including glioblastomas, often require aggressive treatment approaches, which typically involve a combination of surgery, chemotherapy, and radiation therapy
Based on treatment type, the surgery segment accounted for the largest market share in 2024 due to several compelling factors. Firstly, surgical intervention remains the primary approach for managing many types of brain tumors, particularly malignant tumors such as glioblastomas. Surgical procedures, including craniotomy and tumor resection, aim to remove as much of the tumor as possible, which can relieve pressure on the brain, alleviate symptoms, and improve overall patient outcomes

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Research Methodology
1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research in the U.S.
1.4. Information or Data Analysis
- 1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
- 1.6.1. Commodity flow analysis (Model 1)
  - 1.6.1.1. Approach 1: Commodity flow approach
- 1.6.2. Volume price analysis (Model 2)
  - 1.6.2.1. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Tumor Type outlook
- 2.2.2. Treatment Type outlook
2.3. Competitive Insights

Chapter 3. U.S. Brain Tumor Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
- 3.2.1. Market driver analysis
  - 3.2.1.1. Rising prevalence of primary and secondary brain tumors
  - 3.2.1.2. Innovations in diagnostic imaging, surgical techniques (such as advanced neurosurgery), and therapeutic modalities (such as targeted therapies, immunotherapies, and radiotherapy)
  - 3.2.1.3. Increasing awareness and early diagnosis of brain tumor
- 3.2.2. Market restraint analysis
  - 3.2.2.1. High treatment costs
  - 3.2.2.2. Side effects and complications associated with brain tumor treatrment
- 3.2.3. Market opportunity analysis
  - 3.2.3.1. Increasing number of clinical trials
  - 3.2.3.2. Rising fundings and investments from both public and private sectors in research and development activities
- 3.2.4. Market challenge analysis
  - 3.2.4.1. Product recalls
  - 3.2.4.2. Stringent regulations
3.3. U.S. Brain tumor Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Supplier power
  - 3.3.1.2. Buyer power
  - 3.3.1.3. Substitution threat
  - 3.3.1.4. Threat of new entrant
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political landscape
  - 3.3.2.2. Technological landscape
  - 3.3.2.3. Economic landscape

Chapter 4. U.S. Brain Tumor Market: Tumor Type Estimates & Trend Analysis

4.1. Definitions and Scope
4.2. Tumor Type Market Share, 2024 & 2034
4.3. Segment Dashboard
4.4. U.S. Brain Tumor Market by Tumor Type Outlook
4.5. Market Size & Forecasts and Trend Analyses, 2024 to 2034 (Number of Patients Undergo Treatment Per Tumor Type)
- 4.5.1. Malignant
  - 4.5.1.1. Malignant market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
  - 4.5.1.2. Glioblastomas
    - 4.5.1.2.1. Glioblastomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
  - 4.5.1.3. Medulloblastomas
    - 4.5.1.3.1. Medulloblastomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
  - 4.5.1.4. Astrocytomas
    - 4.5.1.4.1. Astrocytomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
  - 4.5.1.5. Ependymomas
    - 4.5.1.5.1. Ependymomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
  - 4.5.1.6. Others
    - 4.5.1.6.1. Others market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
- 4.5.2. Non-Malignant
  - 4.5.2.1. Non-Malignant market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
  - 4.5.2.2. Meningiomas
    - 4.5.2.2.1. Meningiomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
  - 4.5.2.3. Pituitary Adenomas
    - 4.5.2.3.1. Pituitary Adenomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
  - 4.5.2.4. Craniopharyngiomas
    - 4.5.2.4.1. Craniopharyngiomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
  - 4.5.2.5. Hemangioblastomas
    - 4.5.2.5.1. Hemangioblastomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
  - 4.5.2.6. Others
    - 4.5.2.6.1. Others market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)

Chapter 5. U.S. Brain Tumor Market: Treatment Type Estimates & Trend Analysis

5.1. Definitions and Scope
5.2. Treatment Type Market Share, 2024 & 2030
5.3. Segment Dashboard
5.4. U.S. Brain Tumor Market by Treatment Type Outlook
5.5. Malignant Tumor Treatment Type Market Size & Forecasts and Trend Analyses, 2024 to 2034 (Number of Patients per Treatment), USD Million in Terms of Number of Patients per Treatment, Volume (Unit)
- 5.5.1. Surgery
  - 5.5.1.1. Surgery market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
  - 5.5.1.2. Neurosurgical Instruments
    - 5.5.1.2.1. Neurosurgical instruments market estimates and forecast 2024 to 2034 (USD Million)
  - 5.5.1.3. Robotic Surgery Systems
    - 5.5.1.3.1. Robotic surgery systems market estimates and forecast 2024 to 2034 (USD Million)
  - 5.5.1.4. Interventional Device-Based Procedures
    - 5.5.1.4.1. Interventional device-based procedures market estimates and forecast 2024 to 2034 (USD Million)
  - 5.5.1.5. Endoscopes
    - 5.5.1.5.1. Endoscopes market estimates and forecast 2024 to 2034 (USD Million)
  - 5.5.1.6. Intraoperative Imaging Systems
    - 5.5.1.6.1. Intraoperative imaging systems market estimates and forecast 2024 to 2034 (USD Million)
  - 5.5.1.7. Others
    - 5.5.1.7.1. Others market estimates and forecast 2024 to 2034 (USD Million)
- 5.5.2. Radiation Therapy
  - 5.5.2.1. Radiation therapy market estimates and forecast 2024 to 2034 (USD Million)
  - 5.5.2.2. External Beam Radiation Therapy (EBRT)/Stereotactic Radiosurgery (SRS) Devices
    - 5.5.2.2.1. External Beam Radiation Therapy (EBRT)/Stereotactic Radiosurgery (SRS) Devices market estimates and forecast 2024 to 2034 (USD Million)
    - 5.5.2.2.2. Linear Accelerators (LINAC)
      - 5.5.2.2.2.1. Linear Accelerators (LINAC) market estimates and forecast 2024 to 2034 (USD Million)
    - 5.5.2.2.3. Gamma Knife Systems
      - 5.5.2.2.3.1. Gamma knife systems market estimates and forecast 2024 to 2034 (USD Million)
    - 5.5.2.2.4. Proton radiosurgery
      - 5.5.2.2.4.1. Proton radiosurgery market estimates and forecast 2024 to 2034 (USD Million)
  - 5.5.2.3. Internal radiation/Brachytherapy devices
    - 5.5.2.3.1. Internal radiation/brachytherapy devices market estimates and forecast 2024 to 2034 (USD Million)
- 5.5.3. Interventional Device-Based Procedures
  - 5.5.3.1. Interventional device-based procedures market estimates and forecast 2024 to 2034 (USD Million)
  - 5.5.3.2. Embolization Devices
    - 5.5.3.2.1. Embolization devices market estimates and forecast 2024 to 2034 (USD Million)
    - 5.5.3.2.2. Liquid Embolic Agents
      - 5.5.3.2.2.1. Liquid embolic agents market estimates and forecast 2024 to 2034 (USD Million)
    - 5.5.3.2.3. Microspheres
      - 5.5.3.2.3.1. Microspheres market estimates and forecast 2024 to 2034 (USD Million)
  - 5.5.3.3. Tumor Ablation Devices
    - 5.5.3.3.1. Tumor ablation devices market estimates and forecast 2024 to 2034 (USD Million)
- 5.5.4. Chemotherapy
  - 5.5.4.1. Chemotherapy market estimates and forecast 2024 to 2034 (USD Million)
- 5.5.5. Targeted Therapy
  - 5.5.5.1. Targeted therapy market estimates and forecast 2024 to 2034 (USD Million)
- 5.5.6. Tumor Treating Fields (TTF)
  - 5.5.6.1. Tumor Treating Fields (TTF) market estimates and forecast 2024 to 2034 (USD Million)
- 5.5.7. Laser Interstitial Thermal Therapy (LITT)
  - 5.5.7.1. Laser Interstitial Thermal Therapy (LITT) market estimates and forecast 2024 to 2034 (USD Million)
- 5.5.8. Surgically Targeted Radiation Therapy
  - 5.5.8.1. Surgically targeted radiation therapy market estimates and forecast 2024 to 2034 (USD Million)
- 5.5.9. Catheter-Based Ultrasound Thermal Ablation
  - 5.5.9.1. Catheter-based ultrasound thermal ablation market estimates and forecast 2024 to 2034 (USD Million)
- 5.5.10. Focused Ultrasound (FUS)
  - 5.5.10.1. Focused Ultrasound (FUS) market estimates and forecast 2024 to 2034 (USD Million)
- 5.5.11. Low-Intensity Focused Ultrasound (LIFU)
  - 5.5.11.1. Low-Intensity Focused Ultrasound (LIFU) market estimates and forecast 2024 to 2034 (USD Million)
5.6. Non-Malignant Tumor Treatment Type Market Size & Forecasts and Trend Analyses, 2024 to 2034 (Number of Patients per Treatment), USD Million in Terms of Number of Patients per Treatment, Volume (Unit)
- 5.6.1. Surgery
  - 5.6.1.1. Surgery market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
  - 5.6.1.2. Neurosurgical Instruments
    - 5.6.1.2.1. Neurosurgical instruments market estimates and forecast 2024 to 2034 (USD Million)
    - 5.6.1.2.2. Blade, Knife, Cutter & Scissors
      - 5.6.1.2.2.1. Blade, knife, cutter & scissors market estimates and forecast 2024 to 2034 (USD Million)
    - 5.6.1.2.3. Dissector
      - 5.6.1.2.3.1. Dissector market estimates and forecast 2024 to 2034 (USD Million)
    - 5.6.1.2.4. Drill & Perforator
      - 5.6.1.2.4.1. Drill & perforator market estimates and forecast 2024 to 2034 (USD Million)
    - 5.6.1.2.5. Others
      - 5.6.1.2.5.1. Others market estimates and forecast 2024 to 2034 (USD Million)
  - 5.6.1.3. Robotic Surgery Systems
    - 5.6.1.3.1. Robotic surgery systems market estimates and forecast 2024 to 2034 (USD Million)
  - 5.6.1.4. Endoscopes
    - 5.6.1.4.1. Endoscopes market estimates and forecast 2024 to 2034 (USD Million)
  - 5.6.1.5. Intraoperative Imaging Systems
    - 5.6.1.5.1. Intraoperative imaging systems market estimates and forecast 2024 to 2034 (USD Million)
  - 5.6.1.6. Others
    - 5.6.1.6.1. Others market estimates and forecast 2024 to 2034 (USD Million)
- 5.6.2. Radiation Therapy
  - 5.6.2.1. Radiation Therapy market estimates and forecast 2024 to 2034 (USD Million)
  - 5.6.2.2. External Beam Radiation Therapy (EBRT)/Stereotactic Radiosurgery (SRS) Devices
    - 5.6.2.2.1. External Beam Radiation Therapy (EBRT)/Stereotactic Radiosurgery (SRS) Devices market estimates and forecast 2024 to 2034 (USD Million)
    - 5.6.2.2.2. Linear Accelerators (LINAC)
      - 5.6.2.2.2.1. Linear Accelerators (LINAC) market estimates and forecast 2024 to 2034 (USD Million)
    - 5.6.2.2.3. Gamma Knife Systems
      - 5.6.2.2.3.1. Gamma knife systems market estimates and forecast 2024 to 2034 (USD Million)
    - 5.6.2.2.4. Proton radiosurgery
      - 5.6.2.2.4.1. Proton radiosurgery market estimates and forecast 2024 to 2034 (USD Million)
  - 5.6.2.3. Internal radiation/Brachytherapy Devices
    - 5.6.2.3.1. Internal radiation/brachytherapy devices market estimates and forecast 2024 to 2034 (USD Million)
- 5.6.3. Other Monitoring Devices
  - 5.6.3.1. Other monitoring devices market estimates and forecast 2024 to 2034 (USD Million)

Chapter 6. Competitive Landscape

6.1. Recent Developments & Impact Analysis, By Key Market Participants
6.2. Company/Competition Categorization
- 6.2.1. Innovators
6.3. Vendor Landscape
- 6.3.1. List of key distributors and channel partners
- 6.3.2. Key customers
- 6.3.3. Key company market share analysis, 2024
- 6.3.4. GT Medical Technologies, Inc.
  - 6.3.4.1. Company overview
  - 6.3.4.2. Financial performance
  - 6.3.4.3. Product benchmarking
  - 6.3.4.4. Strategic initiatives
- 6.3.5. Novocure
  - 6.3.5.1. Company overview
  - 6.3.5.2. Financial performance
  - 6.3.5.3. Product benchmarking
  - 6.3.5.4. Strategic initiatives
- 6.3.6. ZAP Surgical Systems, Inc.
  - 6.3.6.1. Company overview
  - 6.3.6.2. Financial performance
  - 6.3.6.3. Product benchmarking
  - 6.3.6.4. Strategic initiatives
- 6.3.7. Aesculap, Inc. - a B. Braun company
  - 6.3.7.1. Company overview
  - 6.3.7.2. Financial performance
  - 6.3.7.3. Product benchmarking
  - 6.3.7.4. Strategic initiatives
- 6.3.8. Accuray Incorporated
  - 6.3.8.1. Company overview
  - 6.3.8.2. Financial performance
  - 6.3.8.3. Product benchmarking
  - 6.3.8.4. Strategic initiatives
- 6.3.9. Carthera
  - 6.3.9.1. Company overview
  - 6.3.9.2. Financial performance
  - 6.3.9.3. Product benchmarking
  - 6.3.9.4. Strategic initiatives
- 6.3.10. Alpheus Medical Inc.
  - 6.3.10.1. Company overview
  - 6.3.10.2. Financial performance
  - 6.3.10.3. Product benchmarking
  - 6.3.10.4. Strategic initiatives
- 6.3.11. Alpha Tau Medical Ltd
  - 6.3.11.1. Company overview
  - 6.3.11.2. Financial performance
  - 6.3.11.3. Product benchmarking
  - 6.3.11.4. Strategic initiatives
- 6.3.12. Elekta
  - 6.3.12.1. Company overview
  - 6.3.12.2. Financial performance
  - 6.3.12.3. Product benchmarking
  - 6.3.12.4. Strategic initiatives
- 6.3.13. IMRIS Inc.
  - 6.3.13.1. Company overview
  - 6.3.13.2. Financial performance
  - 6.3.13.3. Product benchmarking
  - 6.3.13.4. Strategic initiatives
- 6.3.14. Medtronic
  - 6.3.14.1. Company overview
  - 6.3.14.2. Financial performance
  - 6.3.14.3. Product benchmarking
  - 6.3.14.4. Strategic initiatives
- 6.3.15. Monteris
  - 6.3.15.1. Company overview
  - 6.3.15.2. Financial performance
  - 6.3.15.3. Product benchmarking
  - 6.3.15.4. Strategic initiatives
- 6.3.16. Openwater
  - 6.3.16.1. Company overview
  - 6.3.16.2. Financial performance
  - 6.3.16.3. Product benchmarking
  - 6.3.16.4. Strategic initiatives
- 6.3.17. Acoustic MedSystems, Inc.
  - 6.3.17.1. Company overview
  - 6.3.17.2. Financial performance
  - 6.3.17.3. Product benchmarking
  - 6.3.17.4. Strategic initiatives
- 6.3.18. NaviFUS Corp
  - 6.3.18.1. Company overview
  - 6.3.18.2. Financial performance
  - 6.3.18.3. Product benchmarking
  - 6.3.18.4. Strategic initiatives
- 6.3.19. Insightec
  - 6.3.19.1. Company overview
  - 6.3.19.2. Financial performance
  - 6.3.19.3. Product benchmarking
  - 6.3.19.4. Strategic initiatives
- 6.3.20. Varian Medical Systems, Inc. (Siemens Healthineers)
  - 6.3.20.1. Company overview
  - 6.3.20.2. Financial performance
  - 6.3.20.3. Product benchmarking
  - 6.3.20.4. Strategic initiatives
- 6.3.21. RefleXion
  - 6.3.21.1. Company overview
  - 6.3.21.2. Financial performance
  - 6.3.21.3. Product benchmarking
  - 6.3.21.4. Strategic initiatives
- 6.3.22. MagnetTx Oncology Solutions Ltd.
  - 6.3.22.1. Company overview
  - 6.3.22.2. Financial performance
  - 6.3.22.3. Product benchmarking
  - 6.3.22.4. Strategic initiatives
- 6.3.23. NICO Corporation (Stryker)
  - 6.3.23.1. Company overview
  - 6.3.23.2. Financial performance
  - 6.3.23.3. Product benchmarking
  - 6.3.23.4. Strategic initiatives
- 6.3.24. Terumo Interventional Systems
  - 6.3.24.1. Company overview
  - 6.3.24.2. Financial performance
  - 6.3.24.3. Product benchmarking
  - 6.3.24.4. Strategic initiatives
- 6.3.25. Boston Scientific Corporation
  - 6.3.25.1. Company overview
  - 6.3.25.2. Financial performance
  - 6.3.25.3. Product benchmarking
  - 6.3.25.4. Strategic initiatives
- 6.3.26. Koninklijke Philips N.V.
  - 6.3.26.1. Company overview
  - 6.3.26.2. Financial performance
  - 6.3.26.3. Product benchmarking
  - 6.3.26.4. Strategic initiatives
- 6.3.27. IBA Worldwide
  - 6.3.27.1. Company overview
  - 6.3.27.2. Financial performance
  - 6.3.27.3. Product benchmarking
  - 6.3.27.4. Strategic initiatives